142 related articles for article (PubMed ID: 36245970)
1. CMTM3 as a Potential New Immune Checkpoint Regulator.
Shen Q; Cong Z; Zhou Y; Teng Y; Gao J; Tang W
J Oncol; 2022; 2022():2103515. PubMed ID: 36245970
[TBL] [Abstract][Full Text] [Related]
2. New prognostic biomarker
Li S; Gao P; Dai X; Ye L; Wang Z; Cheng H
Ann Transl Med; 2022 Feb; 10(4):206. PubMed ID: 35280380
[TBL] [Abstract][Full Text] [Related]
3. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
Front Immunol; 2021; 12():688215. PubMed ID: 34305920
[TBL] [Abstract][Full Text] [Related]
4. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
[TBL] [Abstract][Full Text] [Related]
5. CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer.
Su Y; Lin Y; Zhang L; Liu B; Yuan W; Mo X; Wang X; Li H; Xing X; Cheng X; Dong B; Hu Y; Du H; Zhu Y; Ding N; Li J; Liu W; Ma Y; Qiu X; Ji J; Han W
Cancer Sci; 2014 Jan; 105(1):26-34. PubMed ID: 24131472
[TBL] [Abstract][Full Text] [Related]
6. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
Zhao Q; Gao S; Chen X; Zhu X
Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
[TBL] [Abstract][Full Text] [Related]
7. CMTM3 (CKLF-Like Marvel Transmembrane Domain 3) Mediates Angiogenesis by Regulating Cell Surface Availability of VE-Cadherin in Endothelial Adherens Junctions.
Chrifi I; Louzao-Martinez L; Brandt M; van Dijk CGM; Burgisser P; Zhu C; Kros JM; Duncker DJ; Cheng C
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1098-1114. PubMed ID: 28428220
[TBL] [Abstract][Full Text] [Related]
8. CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer.
Zhou Z; Ma Z; Li Z; Zhuang H; Liu C; Gong Y; Huang S; Zhang C; Hou B
J Cancer; 2021; 12(19):5797-5806. PubMed ID: 34475993
[No Abstract] [Full Text] [Related]
9. Research Advances in CKLFSF-like MARVEL Transmembrane Domain Containing Member 3.
Hu FZ; Sheng ZZ; Qin CP; Xu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Jun; 38(3):360-3. PubMed ID: 27469927
[TBL] [Abstract][Full Text] [Related]
10. Calreticulin, a potential coregulator of immune checkpoints and biomarker associated with tumor microenvironment and clinical prognostic significance in breast invasive carcinoma.
Lin J; Chen Y; Zhang Z; Qi F; Zhang M
Environ Toxicol; 2024 May; 39(5):2717-2731. PubMed ID: 38247288
[TBL] [Abstract][Full Text] [Related]
11. CKLF-Like MARVEL Transmembrane Domain-Containing Member 3 (CMTM3) Inhibits the Proliferation and Tumorigenisis in Hepatocellular Carcinoma Cells.
Li W; Zhang S
Oncol Res; 2017 Jan; 25(2):285-293. PubMed ID: 27629543
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and immunological role of SERPINH1 in pan-cancer.
Zhong H; Wang Z; Wei X; Liu Y; Huang X; Mo X; Tang W
Front Genet; 2022; 13():900495. PubMed ID: 36105106
[No Abstract] [Full Text] [Related]
13. miR-135b-5p promotes gastric cancer progression by targeting CMTM3.
Lu M; Huang Y; Sun W; Li P; Li L; Li L
Int J Oncol; 2018 Feb; 52(2):589-598. PubMed ID: 29345297
[TBL] [Abstract][Full Text] [Related]
14. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells.
Hu F; Yuan W; Wang X; Sheng Z; Yuan Y; Qin C; He C; Xu T
Clin Transl Oncol; 2015 Aug; 17(8):632-9. PubMed ID: 25990505
[TBL] [Abstract][Full Text] [Related]
15. P4HA1, a Prognostic Biomarker that Correlates With Immune Infiltrates in Lung Adenocarcinoma and Pan-Cancer.
Zhao Q; Liu J
Front Cell Dev Biol; 2021; 9():754580. PubMed ID: 34966739
[No Abstract] [Full Text] [Related]
16. Chemokine-like factor-like MARVEL transmembrane domain-containing 3 expression is associated with a favorable prognosis in esophageal squamous cell carcinoma.
Han T; Shu T; Dong S; Li P; Li W; Liu D; Qi R; Zhang S; Zhang L
Oncol Lett; 2017 May; 13(5):2982-2988. PubMed ID: 28521405
[TBL] [Abstract][Full Text] [Related]
17. CMTM3 is frequently reduced in clear cell renal cell carcinoma and exhibits tumor suppressor activities.
Xie J; Yuan Y; Liu Z; Xiao Y; Zhang X; Qin C; Sheng Z; Xu T; Wang X
Clin Transl Oncol; 2014 Apr; 16(4):402-9. PubMed ID: 23907292
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway.
Yuan W; Li T; Mo X; Wang X; Liu B; Wang W; Su Y; Xu L; Han W
Oncotarget; 2016 May; 7(20):29507-19. PubMed ID: 27121055
[TBL] [Abstract][Full Text] [Related]
19. [Knockdown of CMTM3 promotes migration and invasion of PC3 cell in vitro].
Hu FZ; Yuan WQ; Wang XL; Qin CP; Sheng ZZ; DU YQ; Yin HQ; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):594-597. PubMed ID: 29263495
[TBL] [Abstract][Full Text] [Related]
20. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis.
Wang Y; Li J; Cui Y; Li T; Ng KM; Geng H; Li H; Shu XS; Li H; Liu W; Luo B; Zhang Q; Mok TS; Zheng W; Qiu X; Srivastava G; Yu J; Sung JJ; Chan AT; Ma D; Tao Q; Han W
Cancer Res; 2009 Jun; 69(12):5194-201. PubMed ID: 19509237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
